What happened
FDA inspected Zydus Lifesciences Limited in Gujarat from April 15 to 23, 2024, and cited significant CGMP violations involving investigations, aseptic processing, and process validation. FDA stated that multiple cross-contamination events over about three months were linked to inadequate cleaning of shared equipment. Investigations did not cover all potentially affected batches, equipment, product-contact surfaces, or release-test representativeness, and cross-contamination continued after CAPA. FDA also found inadequate investigation of glass particulates in Cyanocobalamin Injection batches; batches underwent repeated visual inspection and were released without an identified root cause, while operator qualification did not adequately reflect commercial inspection conditions. Voluntary recalls covered specified verapamil injection and cyanocobalamin injection batches. In sterile operations, investigators observed disrupted first-air, contact with stoppers during setup, and smoke studies that did not adequately demonstrate unidirectional airflow in the ISO 5 RABS area. FDA further found PPQ programs lacked adequate statistical sampling and acceptance criteria for intra- and inter-batch variability, relied on singular or composite results for critical quality attributes, and omitted data intended to assess vial stoppering and unintended air ingress. FDA deemed its responses inadequate.
Why it matters
From a GMP perspective, incomplete investigations and cleaning studies may leave the scope of nonuniform cross-contamination unresolved, while repeated inspection without root-cause determination may not adequately address glass-particle hazards. Poor aseptic behavior and inconclusive airflow visualization may weaken sterility assurance because interventions can increase contamination risk. PPQ sampling that does not characterize within- and between-batch variability may provide insufficient evidence that processes are controlled. FDA therefore sought broader risk assessments, retrospective reviews, remediation plans, stronger quality-unit oversight, and additional PPQ work.
Key topics: Inadequate investigations of cross-contamination and glass particulates, Poor aseptic behavior and inadequate ISO 5 airflow simulations, PPQ sampling failed to assess intra- and inter-batch variability